Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.42 |
| ▸ | MEP1B | Q16820 | 4/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | FBP1 | P09467 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13853839 | 0.86 | NAMPT (0.47) | PPARGROCK2SLC7A5KMT2AMEN1 | |
| SCHEMBL13853833 | 0.85 | MEN1 (0.45) | PPARGROCK2MEP1BSLC7A5KMT2A | |
| SCHEMBL13853877 | 0.80 | MAPT (0.47) | ROCK2KMT2AMEN1ROCK1 | |
| SCHEMBL13853838 | 0.79 | SLC7A5 (0.55) | PPARGROCK2SLC7A5KMT2AROCK1 | |
| SCHEMBL1692133 | 0.79 | KMT2A (0.47) | PPARGSLC7A5KMT2AMEN1 | |
| SCHEMBL13853836 | 0.78 | ROCK2 (0.61) | ROCK2SLC7A5KMT2ANAMPTROCK1 | |
| SCHEMBL13853740 | 0.77 | F10 (0.54) | ROCK2MEP1BROCK1NR1H4 | |
| SCHEMBL13853832 | 0.77 | KMT2A (0.66) | PPARGROCK2KMT2AMEN1NAMPT | |
| SCHEMBL24721325 | 0.76 | KMT2A (0.45) | PPARGSLC7A5KMT2AMEN1 | |
| SCHEMBL14072399 | 0.76 | KAT6A (0.47) | PPARGKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354418-B2 | Thiazolyl-dihydro-quinazolines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-15 | — | — | US | disclosed |
| US-20090131424-A1 | THIAZOLYL-DIHYDRO-CHINAZOLINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-21 | — | — | US | disclosed |
| US-20070238746-A1 | THIAZOLYL-DIHYDRO-CHINAZOLINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238746-A1 | THIAZOLYL-DIHYDRO-CHINAZOLINE | CYP3A7, UGT2B7, UGT1A7 | PPARG 688/4885ROCK2 1291/4885MEP1B 4043/4885 |
| US-20090131424-A1 | THIAZOLYL-DIHYDRO-CHINAZOLINE | CYP3A7, UGT2B7, UGT1A7 | PPARG 688/4885ROCK2 1291/4885MEP1B 4043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.